We don’t know at this stage how Zantrene protects the heart from chemo damage, just that it must involve more than FTO since the other known FTO inhibitors didn’t provide this protection. We will work it out I am sure (might take some time), but ultimately it is what Zantrene does in patients that really matters, not the molecular mechanism.
- Forums
- ASX - By Stock
- RAC
- Ann: Expanded Heart Protection Discovery for Zantrene
Ann: Expanded Heart Protection Discovery for Zantrene, page-303
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M |
Open | High | Low | Value | Volume |
$1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.44 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 31396 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.440 |
1 | 11250 | 1.390 |
1 | 1000 | 1.380 |
1 | 5000 | 1.370 |
1 | 1279 | 1.365 |
Price($) | Vol. | No. |
---|---|---|
1.450 | 31396 | 1 |
1.480 | 3055 | 2 |
1.500 | 17040 | 2 |
1.520 | 6000 | 1 |
1.575 | 2000 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online